FACTOR RELEATED OF ANTI-TUBERCULOSIS DRUG RESISTENCY ON PULMONARY TUBERCULOSIS PASIENT IN LABUANG BAJI HOSPITAL MAKASSAR
Downloads
Tuberculosis become crucial diseases in the world. The disease can spread rapidly since it spreads through the air. The transmission through coughing and sneezing from droplet TB Patients. Containing Mycobacterium tuberculosis can be exposed to anyone who is around the patient. The aim of this research is to analyze the factors that affect the anti-tuberculosis drug resistance in patients with pulmonary tuberculosis in Labuang Baji Hospital Makassar. The research design is cross sectional approach. This study is conducted in June–July 2017 with a total sample of 60 respondents. Based on the data analysis, it is found that there were 34 respondents (56.7%) from 15–34 years old group and 26 respondents (43.3%) from 35–54 years old group. There were 35 female respondents (58.3%) and 25 male respondent(41.7%), is respondents with positive VCT test result and 45 respondensts (74.0%) with negatif VCT test, 54 respondents (90,0%) who have treatment history previously, 45 respondents (78.3%) have history with TB contact, 45 respondents (75.6%) who had good knowledge. 51 respondents (95%) with anti tuberculosis drug resistance. The result of statistical test using Chi-Square test is showed that there was a significant correlation between treatment history and anti tuberculosis drug resistance with p = 0.024 < α = 0.05. But, there was no relationship between sex and knowledge with anti tuberculosis drug resistance with p value 0.56 and 0.566 (p value > α = 0.05). It is recommended to health worker to give health education for patient and their family, so they can do their treatment until the patients are cured. It can prevent the patient to be anti tuberculosis drug resistance patient.
The Ministry of health. Guidance a national countermeasures tuberculosis. indonesia: Ministry of Health of the Republic of Indonesia; 2014. p. 1–6.
Ministry of health. Profile Health of Indonesia 2015. Indonesia: Ministry Health 2016; 2016. p. 160–7.
Tb E, Region WHOSA. Bending Bending the Curve the Curve ENDING TB ENDING TB in the WHO South-East Asia Region Bending the Curve -Ending TB in the WHO South-East Asia Region.
RSUD Labuang Baji Makassar. Medical Record RSUD Labuang Baji Makassar. 2017.
Weird PB. Risk Factor Associated With Multidrug-Resistant. Tanaffos. 2015;17–21.
Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY. Social behaviour risk factors for drug resistant tuberculosis in mainland china: A meta-analysis. J Int Med Res. 2012;40(2):436–45.
Nofizar D, Nawas A, Burhan E. ’Risk Factors Identification Tubercolosis Multidrug Resistance (MDR-TB). Megazine of Medicine Indonesia. 2010;12.
Tupasi TE, Garfin AMCG, Kurbatova E V, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014. Emerg Infect Dis. 2016 Mar;22(3):491–502.
Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC Infect Dis. 2015 Dec 26;15(1):461.
Dobler CC, Korver S, Batbayar O, Nyamdulam B, Oyuntsetseg S, Tsolmon B, et al. Multidrug-Resistant Tuberculosis in Patients for Whom First-Line Treatment Failed, Mongolia, 2010-2011. Emerg Infect Dis. 2015 Aug;21(8):1451–4.
Mulisa G, Workneh T, Hordofa N, Suaudi M, Abebe G, Jarso G. Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia. Int J Infect Dis. 2015 Oct;39:57–61.
M A, Salih, A M, Merza. Risk factors for multi-drug resistant tuberculosis: a review. Duhok Med J. 2010;4:1–7.
Marahatta SB, Kaewkungwal J, Ramasoota P, Singhasivanon P. Risk factors of Multidrug Resistant Tuberculosis in central Nepal: A pilot study. Kathmandu Univ Med J. 2012 Jun 5;8(4).
Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis. 2009;13(1):68–73.
Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Bin Alwi Z, Naing NN. Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study. J Infect Dev Ctries. 2015 Oct 29;9(10):1076.
Fregona G, Cosme LB, Moreira CMM, Bussular JL, Dettoni V do V, Dalcolmo MP, et al. Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil. Rev Saude Publica. 2017;51.
Daniel O, Osman E. Prevalence and risk factors associated with drug resistant TB in South West, Nigeria. Asian Pac J Trop Med. 2011 Feb;4(2):148–51.
Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali E, et al. Determinants of drug-resistant tuberculosis: Analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5(10):887–93.
Faustini A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006 Feb 1;61(2):158–63.
Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis. 2015 Mar;21(3):409–16.
Andrade SS, Sader HS. Antimicrobial resistance in developing countries. Springer. 2010;249.
SB M. Risk Factors of Multidrug Resistant Tuberculosis in Central Nepal. Kathmandu Universi ty Med J. 2010;32:392–7.
Copyright (c) 2018 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution — You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
